Noselab’s groundbreaking diagnostic platform enables the identification of Alzheimer’s disease (AD) pathology through the simultaneous detection of AD biomarkers at the brain-nose interface (BNI) within the upper nasal cavity.

Drainage of cerebrospinal fluid and the associated neurodegenerative disease biomarkers from the brain to the upper nasal cavity without further organ interferences or the restrictions posed by the blood-brain barrier.
  • Non-invasive
  • Safe
  • User-friendly
  • Accessible
  • Sensitive
The diagnostic platform is particularly suitable for extensive early stage AD screenings, patient stratifi cation as well as monitoring of disease and treatment progression. The diagnostic platform can be extended for the detection of other neurodegenerative diseases as well.

The biomarkers of Alzheimer’s disease (AD) and other neurodegenerative diseases can be detected in the upper nasal cavity close to the skull base – an area referred to as the brain-nose interface (BNI) (fig. 1). This is facilitated by the drainage of cerebrospinal fluid (CSF) via the porous structure-cribriform plate, located at the skull base. The analysis of biomarkers in the nasal CSF (nCSF) collected from the vicinity of BNI has the potential to enable non-invasive detection of AD and other neurodegenerative diseases.

Fig. 1 Brain nose interface (BNI)
The cribriform plate forms the roof of the nasal cavity, embracing the central nervous system in the region of the olfactory bulb. Through this brain-nose interface, CSF and its biomarkers directly drain into the upper nasal cavity.
We at Noselab developed a proprietary diagnostic platform leveraging nCSF particularly for the detection of AD pathology. Our diagnostic platform for AD pathology is based on the detailed quantification of the monomeric and oligomeric states of core AD biomarkers. Furthermore, our diagnostic approach differentiates amyloid-pathology positive (A+) subjects from amyloid-pathology negative (A-) ones, within a cohort of patients with cognitive impairment. For more details regarding the specific AD biomarkers, also read our previous publication here. Noselab’s diagnostic methodology enables safe and non-invasive access to AD biomarkers at the BNI – an area that is in close proximity to the pathology’s origin. This methodology addresses the shortcomings of traditional methods like PET scans and CSF assays, which are inaccessible and invasive in nature. The nCSF based approach has the potential to redefine the diagnostic landscape of not only AD but also possibly other neurodegenerative diseases by enabling early-stage screenings, patient stratification, as well as intraindividual disease and treatment monitoring. This publication was first presented at the esteemed AD/PDTM 2024 conference in Lisbon on March 5–9, 2024. Learn more about our participation and the latest publications here. For a copy of our poster or all other inquiries, please contact: